Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?
Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs.
Overview
GLP-1 drugs for weight loss are such a booming business that it was inevitable the major manufacturers of these wonder drugs would eventually end up in court.
This week, GLP-1 heavyweight Novo Nordisk (NYSE: NVO) sued the leading GLP-1 drugmaker, Eli Lilly (NYSE: LLY), claiming its television ads are deceptive because they state that Lilly's Zepbound is more effective for weight loss than Novo's Wegovy.
Details
One such ad by Eli Lilly claims that "in a study," people using Zepbound lost an average of 50 pounds, while those using Wegovy lost an average of 33 pounds.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.